Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05731908 | A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems | PHASE1 | COMPLETED | 28 | — | — | Feb 21, 2023 | Apr 13, 2023 | Sep 20, 2024 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| BI 690517 mild hepatic impairment (Child-Pugh A) | EXPERIMENTAL | - |
| BI 690517 normal hepatic function | EXPERIMENTAL | control group |
| BI 690517 moderate hepatic impairment (Child-Pugh B) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BI 690517 | DRUG | BI 690517 |
Inclusion Criteria: * Male or female subjects aged at least 18 years at screening * Body mass index of 18.5 to 36.0 kg/m2 (inclusive) * Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial. * Women of childbearing potential1 and ...